The Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market was valued at USD 7.85 billion in 2023 and is projected to reach a market size of USD 13.28 billion by 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 7.8%.
One possible method of treating non-Hodgkin lymphoma is through targeted treatments. Compared to typical chemotherapy, these medicines offer a more targeted approach by taking advantage of certain weaknesses present in cancer cells. Small molecule medications and monoclonal antibodies are two different kinds. Rituximab is one example of a monoclonal antibody that functions like an assassin by binding to proteins on the surface of cancer cells and designating them for the immune system to destroy. Ibrutinib and other small-molecule medications interfere with internal signalling pathways that support the development and survival of cancer cells. Targeted therapies are frequently used in conjunction with other treatments, which may increase their efficacy and lessen their negative effects. They are not a foolproof treatment for NHL, and like other medications, they can have adverse effects that differ from one another. It's important to explore risks and advantages with your doctor if you're thinking about targeted treatment for NHL.
Key Market Insights:
At a compound annual growth rate of 7.8%, the non-Hodgkin lymphoma (NHL) targeted therapy market is projected to reach USD 16.64 billion by 2032 on a global scale. The increasing incidence of NHL worldwide, increased funding for the discovery and development of innovative targeted treatments, and the expanding need for safer and more efficient treatment alternatives are the main drivers of this expansion.
By 2032, the targeted treatment market for NHL is expected to generate USD 9.6 billion from the B-cell lymphoma type segment. The high frequency of B-cell lymphomas and the efficacy of targeted therapy in the treatment of various NHL subtypes account for this dominance.
In 2023, North America accounted for the biggest revenue share of targeted treatments in the treatment of NHL, with a market share of approximately 35.4%. This dominance can be ascribed to elements such as the widespread adoption of pricey targeted medicines, the high prevalence of NHL, and the robust healthcare infrastructure.
Because of its efficacy, immunotherapy is seen as a developing therapeutic option for the treatment of NHL. Because targeted treatments can target certain disease vulnerabilities and may have better side effect profiles than standard chemotherapy, they are still anticipated to play an important role in the treatment of cancer.
Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market Drivers:
Because traditional chemotherapy has limitations, targeted therapies are becoming more popular in the treatment of non-Hodgkin lymphoma.
Due to the shortcomings of conventional chemotherapy, there is a growing need for tailored medicines for the treatment of non-Hodgkin lymphoma (NHL). Chemotherapy is a useful treatment, but it also frequently has serious side effects that can drastically lower a patient's quality of life. These adverse effects might include everything from weariness and nerve damage to nausea and hair loss. Here's where tailored medicines show great promise. Targeted medicines operate like snipers, carefully targeting weaknesses unique to cancer cells, in contrast to the wide approach of chemotherapy. This targeted assault may increase therapy effectiveness while reducing the frequency and intensity of adverse effects. Patients may benefit from better treatment results as a result, possibly leading to an improved quality of life both during and after therapy. The growing market for targeted treatments in the treatment of non-Hodgkin lymphoma is largely due to this shift in preference towards them, which is motivated by the need for both lower toxicity and increased efficacy.
A ray of hope for subtypes that are incurable Targeted Treatments for Non-Hodgkin Lymphoma: Meeting Unmet Needs
Even though targeted medicines have completely changed the way NHL is treated, there are still a lot of unmet medical needs for NHL subtypes. Aggressive subtypes are very difficult to treat and frequently don't have any choices. The market for tailored therapy enters the picture at this point and offers some optimism. Pharmaceutical firms are aggressively developing innovative targeted medicines especially tailored to solve therapy gaps, motivated by a mission to improve patient outcomes. The distinct vulnerabilities of these difficult NHL subtypes are the focus of these next-generation medicines. The market could dramatically enhance NHL treatment options and give hope to patients who had few alternatives in the past by effectively developing tailored medicines for these neglected patient populations. The market for targeted therapies is expanding due in large part to this emphasis on unmet medical needs, which is pushing the envelope in treatment and providing hope for many NHL patients.
Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market Restraints and Challenges:
Although there are obstacles, the worldwide market for targeted treatments for non-Hodgkin lymphoma (NHL) appears promising. Exorbitant expenses restrict patient access, particularly in areas where healthcare finances are tight. The release of these potentially life-saving therapies is delayed by strict constraints. Furthermore, the variety of NHL subtypes makes the creation of treatments that work for everyone difficult. Although tailored medicines provide benefits over conventional methods, they are not infallible. Resistance can grow over time, and some patients might not react at all. Even while side effects from chemotherapy are often less severe, they can still happen. The market is anticipated to expand despite these obstacles because of things like the growing prevalence of NHL, higher funding for research, and patient demand for new treatment alternatives. The process of removing obstacles is in progress. Pharmaceutical firms are working on better treatments with the intention of surpassing resistance and increasing efficacy while lowering prices. Regulatory agencies are looking for methods to speed up approvals without sacrificing security. Additionally, healthcare organisations are looking for ways to increase patient access, such as value-based pricing and more extensive insurance coverage. Targeted treatments hold the potential to transform the treatment of NHL and greatly enhance patient outcomes by surmounting these obstacles.
Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market Opportunities:
Exciting potential abound in the worldwide market for targeted therapeutics for non-Hodgkin lymphoma (NHL). First off, there is a substantial unmet medical need for efficient therapies for NHL subtypes. This offers a fantastic opportunity for businesses to create tailored treatments to fill in these gaps. Second, targeted medicines that are customised to each patient's specific genetic composition and cancer mutations are made possible by advances in precision medicine. Treatments that are more effective and have fewer adverse effects may result from this customised approach. The integration of targeted medicines with other treatments, like as immunotherapy or chemotherapy, is a viable avenue for improving treatment results. Moreover, the growing incidence of NHL in emerging nations opens new markets. This promise may be realised by working together to create cost-effective targeted medicines, establish insurance coverage channels, and improve healthcare infrastructure. Finally, the development of even more potent tailored therapeutics for NHL may be sped up by the application of technology innovations like artificial intelligence and big data. By taking advantage of these chances, the market for NHL-targeted therapies has the potential to develop significantly and contribute significantly to global patient outcomes improvements.
TARGETED THERAPY-BASED NON-HODGKIN LYMPHOMA TREATMENT MARKET REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2023 - 2030 |
|
Base Year |
2023 |
|
Forecast Period |
2024 - 2030 |
|
CAGR |
7.8% |
|
Segments Covered |
By Drug Type, NHL Subtype, Route of Administration, Distribution Channel, and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regional Scope |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Key Companies Profiled |
AbbVie Inc., AstraZeneca, Bayer AG, Bristol Myers Squibb Company, CELGENE CORPORATION (Bristol Myers Squibb Company), Genentech, Inc. (F. Hoffmann-La Roche Ltd), Kite Pharma, Inc. / Gilead Sciences, Inc., Kyowa Kirin Co., Ltd., Merck & Co., Inc., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Janssen Pharmaceuticals, Inc., Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited |
Monoclonal Antibodies
Small Molecule Drugs
Monoclonal antibodies are the undisputed champions in the targeted therapy market for Non-Hodgkin Lymphoma (NHL), boasting the largest and fastest growing segment. Their rise to prominence is fueled by their ability to precisely target cancer cells, proven effectiveness, generally milder side effects, and continuous development of even better versions. While small molecule drugs remain important, monoclonal antibodies are leading the charge in the fight against NHL with targeted therapies.
Diffuse Large B-Cell Lymphoma
Follicular Lymphoma
Mantle Cell Lymphoma
Peripheral T-Cell Lymphoma
Other subtypes
As the biggest and fastest-growing subset of Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL) dominates the targeted treatment market. The reason for this dominance is that DLBCL is the most prevalent NHL subtype, reacts favourably to current treatments like Rituximab, and has generated a lot of interest in further research for more precisely targeted therapies. Although other subtypes also reap benefits, DLBCL's dominant position in this targeted therapy industry is cemented by its prevalence, treatment response, and continued research.
Intravenous
Subcutaneous
Although intravenous (IV) distribution is still the norm, the subcutaneous (sub-q) portion of the targeted treatment market for non-Hodgkin lymphoma (NHL) is growing at an exponential rate. Convenience, maybe shorter hospital stays, and a potentially improved patient experience because of simpler administration and less pain are all benefits of this rapidly expanding approach. Nonetheless, there are now obstacles such as restricted drug supply in sub-q formulations and possible injection site responses. Alongside traditional IV administration, sub-q delivery is set to become a major force as additional treatment choices become accessible sub-q and healthcare practitioners gain confidence with this method.
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
A clear leader in the distribution channels for targeted treatments for non-Hodgkin lymphoma (NHL) is unclear due to the market's complexity. Hospital pharmacies are now the best because of their knowledge, connections to healthcare specialists, and safety procedures. Future expansion of retail pharmacies may be possible if laws are loosened, more pharmacists receive training, and copay assistance programmes proliferate. Strict restrictions and safety concerns impose constraints on online pharmacies, impeding their potential for substantial expansion.
North America
Asia-Pacific
Europe
South America
Middle East and Africa
Due to a combination of variables, the Asia-Pacific region is quickly rising to the top of the Non-Hodgkin Lymphoma (NHL) targeted treatment market. This market is developing because of an increasing number of people who are at risk for NHL, better access to diagnostics and healthcare facilities, more public knowledge of the illness, and developments in the economy that make these pricey medicines more affordable.
COVID-19 Impact Analysis on the Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market:
The market for targeted therapies for non-Hodgkin lymphoma (NHL) was affected by the COVID-19 pandemic. Healthcare concentrated on COVID-19, clinical studies stagnated, and supply systems broke. Then again, opportunities came. The emphasis on healthcare systems may have raised awareness of the NHL and enhanced access to care through telemedicine. Most critically, more research is being done to create safer, more focused treatments for NHL patients with impaired immune systems. The market's ability to overcome these obstacles and seize these new opportunities will determine its destiny.
Recent Trends and Developments in the Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market:
Targeted therapeutics for non-Hodgkin lymphoma (NHL) are seeing rapid innovation in the worldwide market. The emergence of precision medicine, which customises therapies based on each patient's specific genetic composition for better outcomes and fewer adverse effects, is a significant development. To enhance results, researchers are also looking at potent combos of targeted medicines with other medical interventions like immunotherapy. Targeted medicines are also being developed to address unmet medical requirements in certain NHL sub-types, providing much-needed hope to a great number of patients. The search for even more potent tailored medicines is accelerating because of technological innovations like artificial intelligence and big data. There is a new market potential because of the rising NHL burden in developing nations, where efforts are being made to enhance healthcare infrastructure, offer inexpensive medications, and broaden insurance coverage. In addition to interfering with clinical trials and perhaps postponing diagnosis, the COVID-19 pandemic has accelerated the use of telemedicine, which may ultimately increase patient access. Furthermore, the pandemic's emphasis on susceptible groups has accelerated the development of tailored treatments that reduce immunosuppression. The market for targeted therapies in NHL has the potential to transform treatment and greatly enhance patient outcomes by leveraging these promising developments and navigating current obstacles.
Key Players:
AbbVie Inc.
AstraZeneca
Bayer AG
Bristol Myers Squibb Company
CELGENE CORPORATION (Bristol Myers Squibb Company)
Genentech, Inc. (F. Hoffmann-La Roche Ltd)
Kite Pharma, Inc. / Gilead Sciences, Inc.
Kyowa Kirin Co., Ltd.
Merck & Co., Inc.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Janssen Pharmaceuticals, Inc.
Spectrum Pharmaceuticals, Inc.
Takeda Pharmaceutical Company Limited
Global automotive lighting refers to all vehicle lighting systems, from headlamps that illuminate the road to taillights that communicate movements. They guarantee motorists and other road users alike safety, visibility, and style. While taillights frequently use LEDs for improved visibility, headlights are available in a variety of technologies, including LED and laser. Interior illumination, DRLs, and signal lights all have a role to play. This market, which was estimated to be worth $33.64 billion in 2022, is anticipated to rise to $67.39 billion by 2030 because of laws, luxury tastes, safety concerns, and technological developments like OLED taillights and adaptive headlights. Anticipate a future dominated by intelligent, connected, personalized, and sustainable lighting systems that enhance the safety, efficiency, and aesthetic appeal of automobiles.
Car lighting works its magic to provide safety, visibility, and style. Headlights cut through the night, taillights express intent, and interiors shine with comfort. The billion-dollar global business is expected to rise due to consumer demand for high-end experiences, safer roads, and cutting-edge technology. Imagine dynamic messages being painted by taillights, headlights that adjust to the road, and interiors that customize their atmosphere. Driven by technological advancements like linked systems and laser beams, this future is calling. Anticipate even more visually attractive, environmentally friendly, and intelligent lighting to illuminate the way ahead, making cars safer, more efficient, and unquestionably cooler.
In the market for automobile lighting, safety is the driving force behind demand from the public and laws. While automated high beams smoothly react to traffic, adaptive headlights modify their beams so as not to blind other people. With visually striking displays, dynamic taillights convey intentions for braking and turning. Beyond these developments, integrated pedestrian identification and lane departure alerts will soon make roads safer and brighter for everyone.
Luxurious automobile lighting creates a distinct visual identity that goes beyond simple illumination. Personalized interior lighting customizes the driving experience by setting the mood with a range of colours and intensities, while intricate designs and distinctive DRLs modify exteriors. As you approach your automobile at night, welcoming lights lead the way, resulting in an interior that is perfectly lit. Not only is this symphony of light aesthetically pleasing, but it also stands as a tribute to luxury. Upcoming developments like gesture-controlled lighting and holographic displays promise to further enhance the experience.
The worldwide automotive lighting market is undergoing a significant transition towards energy-efficient solutions, as environmental concerns gain prominence. LED technology is leading the way, providing a ray of hope for the environment and drivers alike. LED lights beam brighter and use a lot less energy than conventional halogen lamps. There are some tangible advantages to this. For drivers, this translates to increased fuel economy, which lowers petrol prices and lessens reliance on fossil fuels. Greater air quality and a reduction in the transport sector's contribution to climate change are the results of reduced overall emissions.
Although the global automotive lighting business is booming, there are still unknowns. Difficulties impede growth even as innovation propels it with eye catching features like laser beams and adaptable headlights. These technologies are luxury items due to their high cost and difficult integration, which puts producers' abilities to the test. The worldwide patchwork created by unclear legislation limits the potential of innovation. Durability issues persist, particularly when complex systems are subjected to challenging conditions. Ultimately, a lot of drivers still don't fully understand how these improvements can help them. Together, we can overcome these obstacles. The keys to reducing costs are improved production, more seamless integration, and unified regulations. Their full potential can be realized by educating customers about the safety, efficiency, and aesthetic value of these lighting wonders. By working together, we can pave the way for an even brighter and safer future for vehicle lighting.
It is made possible by advanced LED technology, which gives drivers the ability to customize their illumination for the highest level of comfort and flair. Consumers that care about the environment want greener products, and vehicle lighting complies. While solar- and self-powered lighting technologies offer a future powered by clean energy, energy-efficient LEDs lower pollution. The advent of connected lighting systems heralds a new age. Envision automobiles interacting with infrastructure and one another to minimize accidents and enhance traffic efficiency. Integrated headlights with pedestrian recognition provide unmatched safety, while dramatic taillights with eye-catching displays alert onlookers to your intentions. The possibilities are endless in the future. Gesture-controlled interior illumination, holographic displays projected onto the road, and even light fixtures with self-healing capabilities.
Due to laws requiring safety features like headlights, taillights, and brake lights, exterior lighting presently holds the most market share in the vehicle lighting industry. The dominance of this market is partly attributed to advancements in safety-focused technologies such as adaptive headlights and daytime running lights. The market value of external lighting is increased by the quick adoption of technology like LED bulbs and laser lights, which improve performance and aesthetics. Conversely, the interior lighting market is expected to increase at the fastest rate in the upcoming years. Innovations like ambient lighting and technology breakthroughs like LED and OLED displays, driven by consumer demand for comfort and personalisation, open new possibilities. The spread of sophisticated interior lighting systems is further driven by the growing emphasis on safety and the expansion of the luxury car market.
The worldwide vehicle lighting market is currently dominated by halogen because of its more affordable price, advanced technology, and useful illumination. With its dependable supply chain and affordable option for manufacturers and cost-conscious customers, halogen holds the biggest market share. The fastest-growing market right now is LEDs, which are predicted to shortly overtake halogen. The rapid expansion of LEDs is driven by their higher efficiency, longer lifespan, flexibility in design, and technological breakthroughs including enhanced brightness. Because LEDs use less energy and produce fewer emissions and better fuel economy, they are becoming more and more popular in the changing automotive lighting market.
Passenger automobiles rule the worldwide automotive lighting market. The sheer number of passenger cars produced which surpasses that of business vehicles and fuels the need for lighting systems is the primary cause of this popularity. The growing demand for personal automobiles in developing nations is a result of rising disposable income, which in turn drives the rise of the passenger car market. The importance that consumers place on safety and aesthetics elements helps to drive market expansion. But in the upcoming years, the market for electric and hybrid cars is expected to develop at the quickest rate. The exponential rise of the worldwide electric car market, which is still expanding and shows no signs of slowing down, is what is driving this surge. Specialised lighting solutions are required since electric and hybrid vehicles have different lighting requirements because of their specific functionality and design aesthetics.
Most lighting systems sold nowadays are sold by OEMs (Original Equipment Manufacturers), primarily because manufacturers pre-install lighting systems in new cars. But in the next years, the aftermarket is expected to develop at the quickest rate. This spike in demand for replacement parts, especially lighting systems, can be linked to several variables, one of them being the average age of cars. The industry is expanding because of consumers' growing desire to personalise their cars with aftermarket lighting upgrades such LED upgrades and decorative lighting. The availability and affordability of technologies like adaptive headlights and laser lights in the aftermarket, together with other advancements in lighting technology, are driving demand even more. Moreover, the growing market for electric cars (EVs).
Throughout the forecast period, Asia Pacific is anticipated to be the automotive lighting market with the highest profitability. Over the past few years, Asia Pacific countries like China and India have seen notable increases in automotive manufacturing and sales, primarily in the medium-to premium luxury car segment. Asia Pacific is predicted to see an increase in the manufacturing of passenger cars, with India experiencing the strongest growth rate. Depending on the state of the national economy, the area offers a suitable selection of both high-end and cheap cars. For instance, there is a substantial demand for halogen, Xenon/HID, and LED since China and India produce more economy and mid-range automobiles. On the other hand, luxury car adoption rates are greater in South Korea and Japan, where LED lighting is the norm.
A brief shadow was thrown by COVID-19 over the worldwide automotive lighting market. Production was stopped by lockdowns and supply chain disruptions, while luxury lighting upgrades were shelved by consumers on a tight budget. Resources became scarce, and R&D stagnated. Still, the market is recovering thanks to resurgent demand and rearranged priorities. While energy-efficient LEDs are being pushed towards adoption by sustainability, safety concerns are driving interest in features like pedestrian detection and adaptive headlights. The digital push of the epidemic creates opportunities for intelligent, networked lighting systems that may interact with infrastructure and other cars. Ultimately, the industry is positioned to shine brighter, focused on safety, sustainability, and a connected future, even though the pandemic dimmed its brilliance.
A development collaboration between OSRAM Continental and REHAU aims to incorporate lighting into external components, providing automobile manufacturers with innovative lighting options that improve functionality and design flexibility. For rear combination lamps, Hella unveiled a revolutionary lighting innovation called Hella FlatLight technology. A Memorandum of Understanding (MoU) was signed by Samvardhana Motherson Automotive Systems Group BV (SMRPBV), a division of Motherson Group, and Marelli Automotive Lighting to investigate a technology collaboration focused on intelligently lighted external body components. Valeo debuted their revolutionary 360° lighting system at the Shanghai Auto Show. This technology surrounds the car with a band of light, projecting instantaneous, clear signs that other drivers can see from a distance. Pedestrians, cyclists, and scooter riders are especially susceptible to these signals
The Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market size is valued at USD 7.85 billion in 2023.
The worldwide Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market growth is estimated to be 7.8% from 2024 to 2030.
The Global Targeted Therapy-based Non-Hodgkin Lymphoma Treatment Market is segmented By Drug Type (Monoclonal Antibodies, Small Molecule Drugs); By NHL Subtype (Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Peripheral T-Cell Lymphoma, Other subtypes); By Route of Administration (Intravenous, Subcutaneous); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and by region.
The market for targeted therapeutics for NHL has a promising future thanks to potential including the ongoing development of AI and precision medicine-based more effective medications, the investigation of combination therapies for improved outcomes, and the meeting of unmet medical requirements in certain NHL subtypes. Developing nations also have a significant market potential.
The COVID-19 pandemic delayed clinical studies and may have delayed some patients access to treatment, which affected the market for targeted therapies for non-Hodgkin lymphoma.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
Specify your preferred Countries, Segments, or timeframes
Unlock Country Level Outlook, Trends, Cross-country Comparability, or supply Chain Variations.
Analyst Support
Every order comes with Analyst Support.
Customization
We offer customization to cater your needs to fullest.
Verified Analysis
We value integrity, quality and authenticity the most.
